GregK
Moderator emeritus
- Joined
- Jan 29, 2013
- Messages
- 3,295
- Reason
- PALS
- Diagnosis
- 11/2012
- Country
- US
- State
- CO
- City
- Colorado Springs
Appears to have just fired off recruiting. I can't find any US center emntioned, however.
This is pf II for Ozanezumab (GSK1223249):
Above from ALS Society of Canada
I would think the side effects from an antibody would be less than from a 'drug'...
This is pf II for Ozanezumab (GSK1223249):
Ozanezumab (GSK 1223249) is a drug that targets a protein called Neurite Outgrowth Inhibitor (Nogo-A). It is a monoclonal antibody, which is a substance that the body makes in immunity to prevent the action of a particular protein. Nogo-A blocks neurons from growing toward muscle once the connection has been made. When motor neurons degenerate and the connection becomes weakened, Nogo-A would work against keeping that nerve/muscle contact strong. Increased Nogo-A has been observed in muscle of people with ALS and ozanezumab delayed symptom onset and improved survival in ALS model mice. Thus, it is hoped that it will preserve muscle function and slow the rate of ALS progression in humans.
Above from ALS Society of Canada
I would think the side effects from an antibody would be less than from a 'drug'...